Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3073 | Premier Biotech COVID-19 IgG/IgM Rapid test Cassette Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to assess the efficacy and safety of the administration of anti-SARS-CoV-2 convalescent plasma in COVID-19 patients who are sick enough to warrant hospitalization, but not yet admitted to the ICU (prior to the onset of overwhelming disease including a systemic inflammatory response, sepsis, and/or ARDS).
Description: Disease progression from the state at randomization (with a "3" or "4" on the WHO Ordinal Scale for Clinical Improvement) to requiring invasive mechanical ventilation (which is "6" or greater on the WHO scale) during the study period
Measure: Disease progression measured by WHO scale Time: Day 0 through Day 28 (or hospital discharge)Description: Comparison of the number of participants reaching a maximum daily WHO score of 5, 7, and 8 during the study period per group
Measure: Comparison of maximum WHO score per group Time: Day 0 through Day 28 (or hospital discharge)Description: Comparison of the median and maximum daily WHO scores during the study period per group
Measure: Comparison of decrease of median and maximum WHO score per group Time: Day 0 through Day 28 (or hospital discharge)Description: Comparison of time to clinical improvement, defined as time between randomization and time to improvement (WHO Ordinal Scale "2" first reached for at least 1 day)
Measure: Comparison of time to clinical improvement per group Time: Day 0 through Day 28 (or hospital discharge)Description: Evaluate the time to reach score of at least 6 within 28 days
Measure: Comparison of time to reach score of "6" or greater on the WHO scale Time: Day 0 through Day 28 (or hospital discharge)Description: Evaluate number of days hospitalized
Measure: Comparison of hospital length of stay per group Time: Day 0 through Day 28 (or hospital discharge)Description: Evaluate number of hours in the ICU
Measure: Comparison of ICU length of stay per group Time: Day 0 through Day 28 (or hospital discharge)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports